Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: JAMA Otolaryngol Head Neck Surg. 2015 Dec 1;141(12):1133–1139. doi: 10.1001/jamaoto.2015.2381

Figure 4. Inhibition of TAF-Induced c-Met and p44/42 MAPK Phosphorylation in HNSCC Cells.

Figure 4

Head and neck squamous carcinoma (HNSCC) cells were serum starved for 72 hours and treated with Dulbecco modified Eagle medium alone and recombinant hepatocyte growth factor (HGF) (30 ng/mL) with or without ficlatuzumab (100 µg/mL) for 10 minutes. Cell lysates were analyzed for phospho-c-Met and p44/42 mitogen-activated protein kinase (MAPK) by immunoblotting. Ficlatuzumab inhibited HGF-mediated phosphorylation of c-Met and p44/42 MAPK in (A) HN5, (B) UM-SCC-1, and (C) OSC-19 cells.